Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: anIn VitroEvaluation

  • Matthew L. Rizk, Robert Houle, Grace Hoyee Chan, Mike Hafey, Elizabeth G. Rhee, Xiaoyan Chu
  • Antimicrobial Agents and Chemotherapy, December 2013, ASM Journals
  • DOI: 10.1128/aac.02049-13

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1128/aac.02049-13